ArticleFrontiers in oncology2025
Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance.ACS pharmacology & translational science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The burden of breast cancer is still growing in the Middle East and North Africa (MENA). BC patients typically present with more advanced stages than in Western countries. Limited information is available regarding the safety and efficacy of novel molecules for advanced BC in the Middle East region. The present real-world study evaluated the treatment patterns and survival outcomes of abemaciclib in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic BC (mBC) in Kuwait and Lebanon. Methods: The TRACE study is an observational, retrospective, multicenter, single-arm cohort study. Medical records of HR+/HER2- locally advanced or mBC women were retrieved if they received abemaciclib as part of their treatment in Kuwait and Lebanon. Only patients who received abemaciclib monotherapy or in combination with other treatments for at least three months before data collection were included. Results: Eighty-five patients met the eligibility criteria (Kuwait =42 patients, Lebanon =43). Nearly 57% of the patients received abemaciclib in the first-line setting, 19.8% received it in the second-line, and 16.5% received it at third or later lines of treatment. Abemaciclib 150mg twice daily was administered in combination with other treatments, mainly endocrine therapy, in 95.3% of the patients. Overall, 18 patients (21.4%) had a dose reduction at the end of the third month of abemaciclib treatment. After three months of treatment, the rates of complete response (CR) and partial response (PR) as the best response were 6.9% and 63.8%, respectively, with an objective response rate (ORR) of 70.7%. The 12-month progression-free survival (PFS) was 33.3% in the monotherapy group and 79.6% in the combination group. Conclusion: The present real-world evidence confirms the feasibility and effectiveness, in terms of response rate and PFS, of abemaciclib in patients with HR+/HER2- patients with locally advanced or mBC from Kuwait and Lebanon in the Middle East region.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.